Jean-Charles Soria, MD, PhD; Tony Mok, MD; and Anne White are highlighted.

graphic

The European Society for Medical Oncology (ESMO) bestowed its ESMO Award upon Jean-Charles Soria, MD, PhD, at the ESMO 2018 Congress in Munich, Germany. The award recognizes his contributions to lung cancer research and treatment, including his role in launching early trials of PD-1 and PD-L1 inhibitors. Soria is the senior vice president and head of the Oncology Innovative Medicines unit at MedImmune, U.S. He previously served as a professor of medicine and medical oncology at Université Paris-Sud in Orsay, France, and head of the drug development department at the Institut Gustave Roussy in Villejuif, France.

graphic

Also at the ESMO Congress, Tony Mok, MD, received the ESMO Lifetime Achievement Award for his research on biomarkers and molecularly targeted therapies for lung cancer. Mok has led multiple phase III clinical trials, including a trial on the first-line use of gefitinib (Iressa; AstraZeneca) in patients with EGFR-mutant lung cancer. He is a professor and chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong and a cofounder of the Lung Cancer Research Group, the Chinese Thoracic Oncology Research Group, and the Asia Thoracic Oncology Research Group.

graphic

Anne White beganher roles as senior vice president of Eli Lilly and president of Lilly Oncology on September 1. She succeeds Sue Mahony, PhD, who retired. White joined Lilly as an engineer in 1991 and eventually moved into clinical research and oncology drug development, holding roles as vice president of oncology clinical development and chief operating officer for oncology. Most recently, she served as vice president of portfolio management in the oncology division.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.